

# **2025 Health Plan Ratings Required HEDIS<sup>®</sup>, CAHPS<sup>®</sup> and HOS Measures**

## **Commercial & Medicaid**

**HEDIS MY 2024 & CAHPS MY 2024 (Reporting Year 2025)**

## **Medicare**

**HEDIS MY 2024 (Reporting Year 2025)**

**CAHPS MY 2023 (Reporting Year 2024)**

**HOS MY 2023 (Reporting Year 2024)**

## 2025 HEALTH PLAN RATINGS (HPR) REQUIRED HEDIS, CAHPS AND HOS MEASURES

### Summary of Changes to Measure List:

#### September 2024 Posting

- NCQA expects to remove the following measures from 2025 Health Plan Ratings, pending a vote from NCQA's Standards Committee in October 2024 and Public Comment feedback in November 2024.
  - Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit (*Medicaid product line*).
  - Note: Please take this into consideration when making your Adult vs. Child CAHPS scoring component selection in the HOQ.**
  - Pharmacotherapy for Opioid Use Disorder (*Medicare product line only*).
  - Hospitalization Following Discharge From a Skilled Nursing Facility—30-Day (*Medicare product line only*).

#### April 2024 Posting

- Revised the following measures/indicators:

		Commercial	Medicare	Medicaid
<i>Replace the following measure/indicator:</i>	<i>With this measure/indicator:</i>			
Hemoglobin A1c Control for Patients With Diabetes (HBD)— <i>HbA1c Control (&lt;8%)</i>	Glycemic Status Assessment for Patients With Diabetes (GSD)— <i>Glycemic Status (&lt;8%)</i>	✓	✓	✓
Colorectal Cancer Screening (COL)	ECDS reporting version of Colorectal Cancer Screening (COL-E)	✓	✓	✓ <i>(new for Medicaid product line)</i>
Follow-Up Care for Children Prescribed ADHD Medication (ADD)— <i>Continuation &amp; Maintenance Phase</i>	ECDS reporting version of Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)— <i>Continuation &amp; Maintenance Phase</i>	✓		✓
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)— <i>Blood Glucose and Cholesterol Testing</i>	ECDS reporting version of Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)— <i>Blood Glucose and Cholesterol Testing</i>	✓		✓

- Added the following new measures:

Measure Name	Commercial	Medicare	Medicaid
Colorectal Cancer Screening (COL-E)	<i>(already in commercial product line)</i>	<i>(already in Medicare product line)</i>	✓
Use of Imaging Studies for Low Back Pain (LBP)		✓	
Advance Care Planning (ACP)		✓	
Language Diversity of Membership (LDM)	✓	✓	✓

**HEDIS/CAHPS Measures Required for HP Accreditation—Commercial**

Note: The “Weight” column indicates the weight of the item (maximum value = 3) in the overall score calculation.

HEDIS MY 2024 & CAHPS MY 2024 (Reporting Year 2025)

Measure Name		Display Name	Weight
<b>PATIENT EXPERIENCE</b>			
<b>Getting Care</b>			
	Getting Needed Care (Usually + Always)	Getting care easily	1.5
	Getting Care Quickly (Usually + Always)	Getting care quickly	1.5
<b>Satisfaction With Plan Physicians</b>			
	Rating of Personal Doctor (9 + 10)	Rating of primary care doctor	1.5
	Rating of Specialist Seen Most Often (9 + 10)	Rating of specialists	1.5
	Coordination of Care (Usually + Always)	Coordination of care	1.5
<b>Satisfaction With Plan and Plan Services</b>			
	Rating of Health Plan (9 + 10)	Rating of health plan	1.5
	Rating of All Health Care (9 + 10)	Rating of care	1.5
<b>PREVENTION AND EQUITY</b>			
<b>Children and Adolescent Well-Care</b>			
CIS	Childhood Immunization Status—Combination 10	Childhood immunizations	3
IMA	Immunizations for Adolescents—Combination 2	Adolescent immunizations	3
WCC	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile—Total	BMI percentile assessment	1
<b>Women’s Reproductive Health</b>			
PPC	Prenatal and Postpartum Care—Timeliness of Prenatal Care	Prenatal checkups	1
	Prenatal and Postpartum Care—Postpartum Care	Postpartum care	1
PRS-E	Prenatal Immunization Status—Combination Rate	Prenatal immunizations	1
<b>Equity</b>			
RDM	Race/Ethnicity Diversity of Membership	Race and ethnicity of members	1
LDM	Language Diversity of Membership <i>(NEW MEASURE)</i>	Language preferences of members	0.5
<b>Cancer Screening</b>			
BCS-E	Breast Cancer Screening	Breast cancer screening	1
COL-E	Colorectal Cancer Screening—Total <i>(NEW REPORTING METHOD)</i>	Colorectal cancer screening	1
CCS	Cervical Cancer Screening	Cervical cancer screening	1
<b>Other Preventive Services</b>			
CHL	Chlamydia Screening in Women—Total	Chlamydia screening	1
AIS-E	Adult Immunization Status—Influenza—Total	Influenza immunizations for adults	1
	Adult Immunization Status—Td/Tdap—Total	Td/Tdap immunizations for adults	1
	Adult Immunization Status—Zoster—Total	Zoster immunizations for adults	1
	Adult Immunization Status—Pneumococcal—66+	Pneumococcal immunizations for adults	1

Measure Name		Display Name	Weight
<b>TREATMENT</b>			
<b>Respiratory</b>			
AMR	Asthma Medication Ratio—Total	Asthma control	1
CWP	Appropriate Testing for Pharyngitis—Total	Appropriate testing and care for a sore throat	1
URI	Appropriate Treatment for Upper Respiratory Infection—Total	Appropriate antibiotic use for colds	1
AAB	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Total	Appropriate antibiotic use for acute bronchitis/bronchiolitis	1
PCE	Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid	Steroid after hospitalization for acute COPD	1
	Pharmacotherapy Management of COPD Exacerbation—Bronchodilator	Bronchodilator after hospitalization for acute COPD	1
<b>Diabetes</b>			
BPD	Blood Pressure Control for Patients With Diabetes	Patients with diabetes—blood pressure control (140/90)	3
EED	Eye Exam for Patients With Diabetes	Patients with diabetes—eye exams	1
GSD	Glycemic Status Assessment for Patients With Diabetes—Glycemic Status (<8%) <i>(NEW MEASURE)</i>	Patients with diabetes—glycemic status	3
SPD	Statin Therapy for Patients With Diabetes—Received Statin Therapy	Patients with diabetes—received statin therapy	1
	Statin Therapy for Patients With Diabetes—Statin Adherence 80%	Patients with diabetes—statin adherence 80%	1
KED	Kidney Health Evaluation for Patients with Diabetes—Total	Patients with diabetes—kidney health evaluation	1
<b>Heart Disease</b>			
SPC	Statin Therapy for Patients With Cardiovascular Disease—Received Statin Therapy—Total	Patients with cardiovascular disease—received statin therapy	1
	Statin Therapy for Patients With Cardiovascular Disease—Statin Adherence 80%—Total	Patients with cardiovascular disease—statin adherence 80%	1
CBP	Controlling High Blood Pressure	Controlling high blood pressure	3
<b>Behavioral Health—Care Coordination</b>			
FUH	Follow-Up After Hospitalization for Mental Illness—7 days—Total	Follow-up after hospitalization for mental illness	1
FUM	Follow-Up After Emergency Department Visit for Mental Illness—7 days—Total	Follow-up after ED for mental illness	1
FUA	Follow-Up After Emergency Department Visit for Substance Use—7 days—Total	Follow-up after ED for substance use disorder	1
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder—7 days—Total	Follow-up after high-intensity care for substance use disorder	1
<b>Behavioral Health—Medication Adherence</b>			
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Adherence to antipsychotic medications for individuals with schizophrenia	1

Measure Name		Display Name	Weight
AMM	Antidepressant Medication Management—Effective Continuation Phase Treatment	Patients with a new episode of depression—medication adherence for 6 months	1
POD	Pharmacotherapy for Opioid Use Disorder—Total	Patients with opioid use disorder—medication adherence for 6 months	1
<b>Behavioral Health—Access, Monitoring and Safety</b>			
APM-E	Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total ( <b>NEW REPORTING METHOD</b> )	Cholesterol and blood sugar testing for youth on antipsychotic medications	1
APP	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total	First-line psychosocial care for youth on antipsychotic medications	1
ADD-E	Follow-Up Care for Children Prescribed ADHD Medication—Continuation & Maintenance Phase ( <b>NEW REPORTING METHOD</b> )	Continued follow-up after ADHD diagnosis	1
IET	Initiation and Engagement of Substance Use Disorder Treatment—Engagement of SUD Treatment—Total	Substance use disorder treatment engagement	1
<b>Risk-Adjusted Utilization</b>			
AHU	Acute Hospital Utilization—Observed-to-Expected Ratio—Total Acute—Total	Acute hospital utilization	1
PCR	Plan All-Cause Readmissions—Observed-to-Expected Ratio—18-64 years	Plan all-cause readmissions	1
EDU	Emergency Department Utilization—Observed-to-Expected Ratio—Total	Emergency department utilization	1
<b>Other Treatment Measures</b>			
LBP	Use of Imaging Studies for Low Back Pain—Total	Appropriate use of imaging studies for low back pain	1

### HEDIS/CAHPS/HOS Measures Required for HP Accreditation—Medicare

*HEDIS MY 2024 (Reporting Year 2025); CAHPS MY 2023 (Reporting Year 2024); HOS MY 2023 (Reporting Year 2024)*

Measure Name		Display Name	Weight
<b>PATIENT EXPERIENCE</b>			
<b>Getting Care</b>			
Getting Needed Care (Usually + Always)		Getting care easily	1.5
Getting Care Quickly (Usually + Always)		Getting care quickly	1.5
<b>Satisfaction With Plan Physicians</b>			
Rating of Personal Doctor (9 + 10)		Rating of primary care doctor	1.5
Rating of Specialist Seen Most Often (9 + 10)		Rating of specialists	1.5
Coordination of Care (Usually + Always)		Coordination of care	1.5

Measure Name		Display Name	Weight
<b>Satisfaction With Plan and Plan Services</b>			
Rating of Health Plan (9 + 10)		Rating of health plan	1.5
Rating of All Health Care (9 + 10)		Rating of care	1.5
<b>PREVENTION AND EQUITY</b>			
<b>Cancer Screening</b>			
BCS-E	Breast Cancer Screening	Breast cancer screening	1
COL-E	Colorectal Cancer Screening—Total ( <i>NEW REPORTING METHOD</i> )	Colorectal cancer screening	1
<b>Other Preventive Services</b>			
AIS-E	Adult Immunization Status—Influenza—Total	Influenza immunizations for adults	1
	Adult Immunization Status—Td/Tdap—Total	Td/Tdap immunizations for adults	1
	Adult Immunization Status—Zoster—Total	Zoster immunizations for adults	1
	Adult Immunization Status—Pneumococcal—66+	Pneumococcal immunizations for adults	1
<b>Equity</b>			
RDM	Race/Ethnicity Diversity of Membership	Race and ethnicity of members	1
LDM	Language Diversity of Membership ( <i>NEW MEASURE</i> )	Language preferences of members	0.5
<b>TREATMENT</b>			
<b>Respiratory</b>			
CWP	Appropriate Testing for Pharyngitis—Total	Appropriate testing and care for a sore throat	1
URI	Appropriate Treatment for Upper Respiratory Infection—Total	Appropriate antibiotic use for colds	1
AAB	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Total	Appropriate antibiotic use for acute bronchitis/bronchiolitis	1
PCE	Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid	Steroid after hospitalization for acute COPD	1
	Pharmacotherapy Management of COPD Exacerbation—Bronchodilator	Bronchodilator after hospitalization for acute COPD	1
<b>Diabetes</b>			
BPD	Blood Pressure Control for Patients With Diabetes	Patients with diabetes—blood pressure control (140/90)	3
EED	Eye Exam for Patients With Diabetes	Patients with diabetes—eye exams	1
GSD	Glycemic Status Assessment for Patients With Diabetes—Glycemic Status (<8%) ( <i>NEW MEASURE</i> )	Patients with diabetes—glycemic status	3
SPD	Statin Therapy for Patients With Diabetes—Received Statin Therapy	Patients with diabetes—received statin therapy	1
	Statin Therapy for Patients With Diabetes—Statin Adherence 80%	Patients with diabetes—statin adherence 80%	1

Measure Name		Display Name	Weight
KED	Kidney Health Evaluation for Patients with Diabetes—Total	Patients with diabetes—kidney health evaluation	1
<b>Heart Disease</b>			
SPC	Statin Therapy for Patients With Cardiovascular Disease—Received Statin Therapy—Total	Patients with cardiovascular disease—received statin therapy	1
	Statin Therapy for Patients With Cardiovascular Disease—Statin Adherence 80%—Total	Patients with cardiovascular disease—statin adherence 80%	1
CBP	Controlling High Blood Pressure	Controlling high blood pressure	3
<b>Behavioral Health—Care Coordination</b>			
FUH	Follow-Up After Hospitalization for Mental Illness—7 days—Total	Follow-up after hospitalization for mental illness	1
FUM	Follow-Up After Emergency Department Visit for Mental Illness—7 days—Total	Follow-up after ED for mental illness	1
FUA	Follow-Up After Emergency Department Visit for Substance Use—7 days—Total	Follow-up after ED for substance use disorder	1
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder—7 days—Total	Follow-up after high-intensity care for substance use disorder	1
<b>Behavioral Health—Medication Adherence</b>			
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Adherence to antipsychotic medications for individuals with schizophrenia	1
<del>POD*</del>	<del>Pharmacotherapy for Opioid Use Disorder—Total</del>	<del>Patients with opioid use disorder—medication adherence for 6 months</del>	<del>1</del>
AMM	Antidepressant Medication Management—Effective Continuation Phase Treatment	Patients with a new episode of depression—medication adherence for 6 months	1
<b>Behavioral Health—Access, Monitoring and Safety</b>			
IET	Initiation and Engagement of Substance Use Disorder Treatment—Engagement of SUD Treatment—Total	Substance use disorder treatment engagement	1
<b>Patient Safety and Treatment for Older Adults</b>			
PSA	Non-Recommended PSA-Based Screening in Older Men	Avoiding non-recommended prostate cancer screening in older men	1
DDE	Potentially Harmful Drug Disease Interactions in Older Adults—Total	Avoiding potentially harmful drug and disease interactions in older adults	1
DAE	Use of High-Risk Medications in Older Adults—Total Rate (Rate 3)	Avoiding high-risk medications for older adults	1
FRM	Fall Risk Management—Managing Fall Risk	Managing risk of falls	1
OMW	Osteoporosis Management in Women Who Had a Fracture	Managing osteoporosis in women after fracture	1
OSW	Osteoporosis Screening in Older Women	Screening for osteoporosis in women	1

**\*Note:** NCQA expects to remove this measure from 2025 Health Plan Ratings. See Summary of Change note for September 2024 Update.

Measure Name		Display Name	Weight
<b>Care Coordination</b>			
FMC	Follow-Up After Emergency Department Visit for People With Multiple High-Risk Chronic Conditions—65+	Follow-up after ED for multiple high-risk chronic conditions	1
TRC	Transitions of Care—Notification of Inpatient Admission—65+	Transitions of Care—notification of inpatient admission	1
	Transitions of Care—Receipt of Discharge Information—65+	Transitions of Care—receipt of discharge information	1
	Transitions of Care—Patient Engagement After Inpatient Discharge—65+	Transitions of Care—patient engagement after inpatient discharge	1
	Transitions of Care—Medication Reconciliation Post-Discharge—65+	Transitions of Care—medication reconciliation post-discharge	1
ACP	Advance Care Planning ( <b>New Measure</b> )	Advance care planning	1
<b>Risk-Adjusted Utilization</b>			
PCR	Plan All-Cause Readmissions—Observed-to-Expected Ratio—65+	Plan all-cause readmissions	1
EDU	Emergency Department Utilization—Observed-to-Expected Ratio—65+	Emergency department utilization	1
AHU	Acute Hospital Utilization—Observed-to-Expected Ratio—Total Acute—65+	Acute hospital utilization	1
HPC	Hospitalization for Potentially Preventable Complications—Total ACSC—Observed-to-Expected Ratio—Total	Hospitalization for potentially preventable complications	1
<del>HFS*</del>	<del>Hospitalization Following Discharge From a Skilled Nursing Facility—30 Day—Total</del>	<del>Hospitalization following SNF discharge</del>	<del>4</del>
<b>Other Treatment Measures</b>			
LBP	Use of Imaging Studies for Low Back Pain—Total ( <b>NEW MEASURE</b> )	Appropriate use of imaging studies for low back pain	1

### HEDIS/CAHPS Measures Required for HP Accreditation—Medicaid

HEDIS MY 2024 & CAHPS MY 2024 (Reporting Year 2025)

Measure Name		Display Name	Weight
<b>PATIENT EXPERIENCE</b>			
<b>Getting Care</b>			
Getting Needed Care (Usually + Always)		Getting care easily	1.5
Getting Care Quickly (Usually + Always)		Getting care quickly	1.5
<b>Satisfaction With Plan Physicians</b>			
Rating of Personal Doctor (9 + 10)		Rating of primary care doctor	1.5
<b>Satisfaction With Plan and Plan Services</b>			
Rating of Health Plan (9 + 10)		Rating of health plan	1.5
Rating of All Health Care (9 + 10)		Rating of care	1.5

**\*Note:** NCQA expects to remove this measure from 2025 Health Plan Ratings. See Summary of Change note for September 2024 Update.



Measure Name		Display Name	Weight
<b>PREVENTION AND EQUITY</b>			
<b>Children and Adolescent Well-Care</b>			
CIS	Childhood Immunization Status—Combination 10	Childhood immunizations	3
IMA	Immunizations for Adolescents—Combination 2	Adolescent immunizations	3
WCC	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents—BMI Percentile—Total	BMI percentile assessment	1
<b>Women's Reproductive Health</b>			
PPC	Prenatal and Postpartum Care—Timeliness of Prenatal Care	Prenatal checkups	1
	Prenatal and Postpartum Care—Postpartum Care	Postpartum care	1
PRS-E	Prenatal Immunization Status—Combination Rate	Prenatal immunizations	1
<b>Cancer Screening</b>			
BCS-E	Breast Cancer Screening	Breast cancer screening	1
COL-E	Colorectal Cancer Screening—Total <i>(NEW MEASURE)</i>	Colorectal cancer screening	1
CCS	Cervical Cancer Screening	Cervical cancer screening	1
<b>Equity</b>			
RDM	Race/Ethnicity Diversity of Membership	Race and ethnicity of members	1
LDM	Language Diversity of Membership <i>(NEW MEASURE)</i>	Language preferences of members	0.5
<b>Other Preventive Services</b>			
CHL	Chlamydia Screening in Women—Total	Chlamydia screening	1
<del>MSC*</del>	<del>Medical Assistance With Smoking and Tobacco Use Cessation—Advising Smokers and Tobacco Users to Quit</del>	<del>Smoking advice</del>	<del>4</del>
AIS-E	Adult Immunization Status—Influenza—Total	Influenza immunizations for adults	1
	Adult Immunization Status—Td/Tdap—Total	Td/Tdap immunizations for adults	1
	Adult Immunization Status—Zoster—Total	Zoster immunizations for adults	1
	Adult Immunization Status—Pneumococcal—66+	Pneumococcal immunizations for adults	1
<b>TREATMENT</b>			
<b>Respiratory</b>			
AMR	Asthma Medication Ratio—Total	Asthma control	1
CWP	Appropriate Testing for Pharyngitis—Total	Appropriate testing and care for a sore throat	1
AAB	Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis—Total	Appropriate antibiotic use for acute bronchitis/bronchiolitis	1

**\*Note:** NCQA expects to remove this measure from 2025 Health Plan Ratings. See Summary of Change note for September 2024 Update.

Measure Name		Display Name	Weight
PCE	Pharmacotherapy Management of COPD Exacerbation—Systemic Corticosteroid	Steroid after hospitalization for acute COPD	1
	Pharmacotherapy Management of COPD Exacerbation—Bronchodilator	Bronchodilator after hospitalization for acute COPD	1
<b>Diabetes</b>			
BPD	Blood Pressure Control for Patients With Diabetes	Patients with diabetes—blood pressure control (140/90)	3
EED	Eye Exam for Patients With Diabetes	Patients with diabetes—eye exams	1
GSD	Glycemic Status Assessment for Patients With Diabetes—Glycemic Status (<8%) <i>(NEW MEASURE)</i>	Patients with diabetes—glycemic status	3
SPD	Statin Therapy for Patients With Diabetes—Received Statin Therapy	Patients with diabetes—received statin therapy	1
	Statin Therapy for Patients With Diabetes—Statin Adherence 80%	Patients with diabetes—statin adherence 80%	1
KED	Kidney Health Evaluation for Patients With Diabetes—Total	Patients with diabetes—kidney health evaluation	1
<b>Heart Disease</b>			
SPC	Statin Therapy for Patients With Cardiovascular Disease—Received Statin Therapy—Total	Patients with cardiovascular disease—received statin therapy	1
	Statin Therapy for Patients With Cardiovascular Disease—Statin Adherence 80%—Total	Patients with cardiovascular disease—statin adherence 80%	1
CBP	Controlling High Blood Pressure	Controlling high blood pressure	3
<b>Behavioral Health—Care Coordination</b>			
FUH	Follow-Up After Hospitalization for Mental Illness—7 days—Total	Follow-up after hospitalization for mental illness	1
FUM	Follow-Up After Emergency Department Visit for Mental Illness—7 days—Total	Follow-up after ED for mental illness	1
FUA	Follow-Up After Emergency Department Visit for Substance Use—7 days—Total	Follow-up after ED for substance use disorder	1
FUI	Follow-Up After High-Intensity Care for Substance Use Disorder—7 days—Total	Follow-up after high-intensity care for substance use disorder	1
<b>Behavioral Health—Medication Adherence</b>			
SAA	Adherence to Antipsychotic Medications for Individuals With Schizophrenia	Adherence to antipsychotic medications for individuals with schizophrenia	1
AMM	Antidepressant Medication Management—Effective Continuation Phase Treatment	Patients with a new episode of depression—medication adherence for 6 months	1
POD	Pharmacotherapy for Opioid Use Disorder—Total	Patients with opioid use disorder—medication adherence for 6 months	1
<b>Behavioral Health—Access, Monitoring and Safety</b>			
APM-E	Metabolic Monitoring for Children and Adolescents on Antipsychotics—Blood Glucose and Cholesterol Testing—Total <i>(NEW REPORTING METHOD)</i>	Cholesterol and blood sugar testing for youth on antipsychotic medications	1

	Measure Name	Display Name	Weight
ADD-E	Follow-Up Care for Children Prescribed ADHD Medication—Continuation & Maintenance Phase <i>(NEW REPORTING METHOD)</i>	Continued follow-up after ADHD diagnosis	1
SSD	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	Diabetes screening for individuals with schizophrenia or bipolar disorder	1
APP	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics—Total	First-line psychosocial care for youth on antipsychotic medications	1
IET	Initiation and Engagement of Substance Use Disorder Treatment—Engagement of SUD Treatment—Total	Substance use disorder treatment engagement	1
<b>Risk-Adjusted Utilization</b>			
PCR	Plan All-Cause Readmissions—Observed-to-Expected Ratio—18-64	Plan all-cause readmissions	1
<b>Other Treatment Measures</b>			
LBP	Use of Imaging Studies for Low Back Pain—Total	Appropriate use of imaging studies for low back pain	1

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).